(Q38295826)

1 September 2017

1 reference

title

Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection (English)

1 reference

1 September 2017

2

Patrick Marcellin

1 reference

1 September 2017

Tarik Asselah

1

1 reference

1 September 2017

language of work or name

1 reference

1 January 2015

1 reference

1 September 2017

1 reference

1 September 2017

volume

35 Suppl 1

1 reference

1 September 2017

page(s)

56-64

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 September 2017

cites work

1 reference

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

Efficient initiation of HCV RNA replication in cell culture

21 January 2018

1 reference

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

Structure of the hepatitis C virus RNA helicase domain

21 January 2018

1 reference

Genomics and HCV infection: progression of fibrosis and treatment response

21 January 2018

1 reference

In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C.

21 January 2018

1 reference

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

21 January 2018

1 reference

Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C

21 January 2018

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

Hepatitis C virus resistance to protease inhibitors

21 January 2018

1 reference

Sofosbuvir for the treatment of hepatitis C virus

21 January 2018

1 reference

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?

21 January 2018

1 reference

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a

21 January 2018

1 reference

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre

21 January 2018

1 reference

Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity

21 January 2018

1 reference

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12745

1 reference

1 September 2017

1 reference